ShinyHunters Breached 300 Oracle PeopleSoft Servers
ShinyHunters confirms breaching 300 Oracle PeopleSoft instances at 100+ organizations, with zero-days in play and universities hit first.
ShinyHunters confirms breaching 300 Oracle PeopleSoft instances at 100+ organizations, with zero-days in play and universities hit first.
CFTC's prediction market rule proposes a categorical bar on war and terrorism bets, citing assassination-plot conflicts of interest.
Amazon's $17.5B delayed-draw loan carries a Sept. 30 draw deadline and zero financial covenants, built to fund a $200B AI capex push.
ServiceNow patched an open API silently on June 5, then disclosed attackers had queried customer tables four days later. Shares fell on disclosure.
Sanofi pulled the MOBILIZE phase 3 after an independent DMC found riliprubart unlikely to deliver, leaving $555M in projected CIDP sales at risk.
$38B Visa-Mastercard swipe fee deal gets preliminary court nod, but the NRF says the fee cut just rolls rates back to 2023 levels.
Lilly's $25.27B deal spree in 2026 eclipses the combined M&A of every other top-12 pharma, and the obesity juggernaut isn't done yet.
Qilin ransomware hit a few dozen organizations through a CVSS 9.3 Check Point VPN flaw before a patch existed. Agencies have until June 11.
Colorado's DIDMCA opt-out drew an amicus coalition of FDIC, OCC, 21 state AGs, and the U.S. Chamber against it in the Tenth Circuit.
SoFi's Hong Kong unit discovered a vendor breach on April 30 but can't say who was hit, what was taken, or whether the vendor was extorted.
Lilly's retatrutide hits 30.3% weight loss at two years while Novo Nordisk's oral Wegovy crosses 3 million scripts and queues two H2 FDA decisions.
Meta caught NSO running phishing campaigns in violation of a court-ordered no-hack ban, and it's now asking a federal judge for contempt.
J&J dropped $1 billion on a preclinical KRAS degrader platform at the exact moment Revolution Medicines proved the target is druggable.
Intesa Sanpaolo bid $35.3 billion for Monte Paschi at a 12.5% premium, blocking a BPM merger-of-equals offer that never named a price.
Roche drops $700M upfront and up to $3B total for Nurix's bexobrutideg, a BTK degrader headed into a phase 3 showdown with Lilly's Jaypirca.